Recently, the B cell has emerged as a cornerstone of systemic lupus erythematosus (SLE)
pathogenesis. This has been highlighted by studies of the cytokine B‐cell‐activating factor of …

B-cell activating factor (BAFF), a member of the family of TNF-like cytokines, supports the
survival and differentiation of B cells. The successful development of belimumab, a human …

B cell-activating factor of the TNF family (BAFF) is an essential B cell survival factor.
However, high levels of BAFF promote systemic lupus erythematosus (SLE) in mice and …

Systemic lupus erythematosus (SLE) is a complex immune disorder in which loss of
tolerance to nucleic acid antigens and other cross‐reactive antigens is associated with the …

BAFF (BLyS) and APRIL are TNF-like cytokines that support survival and differentiation of B
cells. Recent studies have discovered a role for BAFF in augmenting both innate and …

B cells have multiple roles in immune activation and inflammation separate from their
capacity to produce antibodies. B cell depletion is currently under intense investigation as a …

The B cell activating factor (BAFF) inhibitor, belimumab, is the first biologic drug approved for
the treatment of SLE, and exhibits modest, but durable, efficacy in decreasing disease flares …

The B cell activating factor (BAFF), or B lymphocyte stimulator (BLyS), is a B cell survival
factor which supports autoreactive B cells and prevents their deletion. BAFF expression is …

Given the prominent role currently assigned to B lymphocytes in systemic lupus
erythematosus, it is not surprising that the B cell activity factor belonging to the tumor …

Purpose and methods B cell-activating factor (BAFF) contributes to the pathogenesis of
autoimmune diseases including systemic lupus erythematosus (SLE). Although several anti …